The Borrelia Western Blot IgG (Immunoglobulin G) is a vital component in the diagnostic process for Lyme disease, an infection caused by the bacterium Borrelia burgdorferi. IgG antibodies are part of the body’s adaptive immune response and typically develop weeks to months after initial infection, indicating either past exposure or a current, longer-term immune response. Because Lyme disease is a complex, multi-stage illness with varying symptomatology depending on the stage, the IgG Western Blot test provides valuable insights, especially in patients with symptoms that suggest chronic or late-stage infection.

From ticks and small rodents

The Borrelia Western Blot (WB) IgM test is a significant tool in the diagnosis of Lyme disease, an infection caused by the Borrelia burgdorferi bacteria, transmitted primarily through tick bites. The IgM test specifically detects early immune responses to the bacteria and is a valuable marker during the initial weeks following exposure. The presence of IgM antibodies, which are the first line of defense, provides insight into whether an infection is recent, as IgM antibodies typically appear within one to two weeks of exposure and may decline after a few months. Given that Lyme disease can present with a range of symptoms that mimic other illnesses, accurately interpreting IgM and other biomarkers is essential for both timely treatment and effective management of the disease.

The Bradyrhizobiaceae is a family of bacteria within the order Rhizobiales, known primarily for their role in nitrogen fixation in soil. However, their presence in the human gut microbiome, although less commonly discussed, is gaining attention for potential health implications. These bacteria are Gram-negative and possess unique metabolic capabilities that could influence gut health. In the context of the gut microbiome, the role of Bradyrhizobiaceae is not as extensively studied as other bacterial families, yet emerging research suggests they might contribute to the metabolic diversity of the gut flora.

Beta Nerve Growth Factor (β-NGF) is a neurotrophic protein that supports the growth, survival, maintenance, and repair of neurons throughout the nervous system. In the Alzheimer's LINX™ panel, this marker measures immune reactivity to β-NGF rather than NGF levels themselves. Elevated results may indicate that the immune system has developed antibodies against this important neurological growth factor. This marker does not diagnose Alzheimer's disease and should be interpreted alongside other neurological and immune-reactivity biomarkers.

- Each of the BCAAs is catabolized by a dehydrogenase enzyme forming branched-chain keto acids (BDKA), or 2-oxo acids. The dehydrogenase enzyme is heavily dependent on B-complex vitamins, the lack of which may decrease pathway function, possibly leading to an elevation of the BCKA.

- Early research found a vitamin B1 (thiamin)-responsive form of maple syrup urine disease (MSUD).

- Higher urinary BCKA was found to decrease with B-complex vitamins supplementation.

- Evaluate intake of B-complex, primarily thiamin (B1).

- Evaluate dietary intake or supplementation with branched-chain amino acids.